

Evaluation Report for Category B, Subcategory 3.11 Application

Application Number: 2024-0897

Application: New or Changes to Product Labels – New Pests **Applicant:** Adama Agricultural Solutions Canada Ltd.

Product: Maxentis **Registration Number:** 34963

Active ingredients (a.i.): Azoxystrobin and prothioconazole

PMRA Document Number: 3613984

Background

Maxentis is an emulsifiable concentrate fungicide, containing the active ingredients azoxystrobin (120 g/L) and prothioconazole (90 g/L). It is currently registered for use on lowbush blueberry, canola, pea, lentil, soybean, barley, wheat and oats to control or suppress certain fungal diseases.

Purpose of Application

The purpose of this application is to expand the registration of Maxentis to add claims of control of virulent blackleg on canola, and ascochyta blight on lentil. Maxentis is already registered for the control of other diseases on the two subject crops.

Chemistry, Health and Environmental Assessment

A chemistry assessment was not required since there was no change to product chemistry. Health and environment assessments were not required since the use pattern remained unchanged.

Value Assessment

Results from eight efficacy trials conducted on canola and lentil in Alberta and Manitoba in 2022 and 2023 were reviewed to support the claims of control of virulent blackleg on canola, and control of ascochyta blight on lentil. The efficacy results demonstrated that Maxentis controlled the subject diseases on canola and lentil when applied according to label directions under moderate disease pressure. The registration of these new claims provides Canadian growers an additional option for managing these important diseases of canola and lentil.

Conclusion

The PMRA has completed an assessment of the information provided in support of the product, Maxentis, and has found the information sufficient to add the following on the product label:

1) control of virulent blackleg at 1.042 L/ha on canola with one application per year at the 2 – 6 true leaf stage; and



ns per year.

References

3562478	2024, 10.1 Value Summary Maxentis 26Feb2024, DACO: 10.1,10.2.1,10.2.2,10.2.3.1,10.3.1,
	10.3.2,10.3.2(B),10.3.3,10.5.1,10.5.2,10.5.3,10.5.4,10.5.5
3562480	2024, Trial 5 MNT_CA-FU-32812222-MAXBL-CANRTF, DACO: 10.2.3
3562481	2024, Trial 6 SWSRC-23-ADAMA-BL-CANOLARTF, DACO: 10.2.3
3562482	2024, Trial 12 ADAMA 22 MAX LEN 03RTF Ascochyta, DACO: 10.2.3
3562483	2024, Trial 13 Adama23 Post ADF16 Ascochyta Lentil 20, DACO: 10.2.3
3562484	2024, Trial 14 Adama23 Post FOL Ascochyta Lentil 21RTF, DACO: 10.2.3
3562485	2024, Trial 15 Adama23 Post MAX Asco Lentil 27., DACO: 10.2.3
3562486	2024, Trial 16 CA-FU-33100723-FOL-LEN_RTF, DACO: 10.2.3
3562487	2024, Trial 17 CA-FU-33154623-MAX-LENRTF, DACO: 10.2.3

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.